Company ·
Corxel Pharmaceuticals holds a peptide molecule tracked on the Peptide Exchange board.
Corxel Pharmaceuticals has 1 molecule on the board and 1 news move logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
Small molecule agonist of the GLP 1 receptor
Corxel Pharmaceuticals licensed this oral GLP 1 agonist from Vincentage Pharma in 2024. US phase 2 weight loss reached 11.5 percent at 36 weeks; a global phase 3 is planned for 2027.
Log
Corxel Pharmaceuticals will go public through Amanat Acquisition Corp to fund a global phase 3 trial of its daily GLP 1 pill. Phase 2 weight loss reached 11.5 percent at 36 weeks, and tolerability is the claim the trial must prove.
Holds P2